Instituto Rosenbusch (BUE:ROSE) Other Current Assets: ARS755 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:ROSE Instituto Rosenbusch SA BUE:ROSE
37 GF Score
Price ARS154.00
GF Value ARS62.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Instituto Rosenbusch Other Current Assets?

Instituto Rosenbusch BUE:ROSE 37 Other Current Assets is ARS755 Mil as of Dec. 2025. GuruFocus rates BUE:ROSE with a GF Score™ of 37/100 and a GF Value™ of ARS62.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Instituto Rosenbusch's other current assets for the quarter that ended in Dec. 2025 was ARS755 Mil.

Instituto Rosenbusch's quarterly other current assets increased from Jun. 2025 (ARS323 Mil) to Sep. 2025 (ARS537 Mil) and increased from Sep. 2025 (ARS537 Mil) to Dec. 2025 (ARS755Mil).

Instituto Rosenbusch's annual other current assets increased from Dec. 2023 (ARS155 Mil) to Dec. 2024 (ARS309 Mil) increased from Dec. 2024 (ARS309 Mil) to Dec. 2025 (ARS755 Mil).


Instituto Rosenbusch Other Current Assets Related Terms


Instituto Rosenbusch Other Current Assets Historical Data

* Premium members only.

The historical data trend for Instituto Rosenbusch's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch Other Current Assets Chart

Instituto Rosenbusch Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.18 285.05 155.02 309.24 754.59

Instituto Rosenbusch Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 309.24 340.38 322.91 536.92 754.59
BUE:ROSE
37GF Score
Instituto Rosenbusch SA BUE:ROSE
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Instituto Rosenbusch Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of ARS755 Mil mean?
Instituto Rosenbusch (BUE:ROSE) has a Other Current Assets of ARS755 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Instituto Rosenbusch.
Is Instituto Rosenbusch's Other Current Assets too high?
Instituto Rosenbusch's current Other Current Assets is ARS755 Mil. Overall, Instituto Rosenbusch has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Other Current Assets compare to ZTS and UTHR?
Instituto Rosenbusch's Other Current Assets of ARS755 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Instituto Rosenbusch. Instituto Rosenbusch's current Other Current Assets is ARS755 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS62.41, compared to a current price of ARS154.00 — trading 146.8% above its estimated fair value. The current Other Current Assets is ARS755 Mil. Instituto Rosenbusch's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Other Current Assets is ARS755 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?

Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued. The current stock price of ARS154.00 is trading 146.8% above its estimated GF Value™ of ARS62.41. GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.

Key valuation signals for BUE:ROSE:

  • Other Current Assets: ARS755 Mil
  • GF Value™: ARS62.41 vs. price of ARS154.00 (146.8% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Instituto Rosenbusch Business Description

Address Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
37GF Score

Get the complete analysis for BUE:ROSE

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS154.00
Price
ARS62.41
GF Value